Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) Invested Capital (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Invested Capital for 6 consecutive years, with $4.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 22.88% year-over-year to $4.3 billion, compared with a TTM value of $4.3 billion through Dec 2025, down 22.88%, and an annual FY2025 reading of $5.2 billion, down 24.6% over the prior year.
  • Invested Capital was $4.3 billion for Q4 2025 at Roivant Sciences, down from $4.8 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $7.0 billion in Q4 2023 and bottomed at $1.7 billion in Q3 2023.
  • Average Invested Capital over 5 years is $3.6 billion, with a median of $2.3 billion recorded in 2021.
  • The sharpest move saw Invested Capital soared 287.73% in 2023, then dropped 24.6% in 2025.
  • Year by year, Invested Capital stood at $2.2 billion in 2021, then decreased by 19.8% to $1.8 billion in 2022, then skyrocketed by 287.73% to $7.0 billion in 2023, then fell by 20.78% to $5.5 billion in 2024, then fell by 22.88% to $4.3 billion in 2025.
  • Business Quant data shows Invested Capital for ROIV at $4.3 billion in Q4 2025, $4.8 billion in Q3 2025, and $4.8 billion in Q2 2025.